Transporter-mediated drug interaction strategy for 5-aminolevulinic acid (ALA)-based photodynamic diagnosis of malignant brain tumor: Molecular design of ABCG2 inhibitors

Pharmaceutics

Volumn 3, Issue 3, 2011, Pages 615-635

  Ishikawa, Toshihisa ^a   Takahashi, Kenkichi ^b   Ikeda, Naokado ^b   Kajimoto, Yoshinaga ^b   Hagiya, Yuichiro ^c   Ogura, Shun ichiro ^c   Miyatake, Shin ichi ^b   Kuroiwa, Toshihiko ^b  

^a RIKEN YOKOHAMA INSTITUTE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

5 aminolevulinic acid (ALA); ABC transporter; ABCG2; Brain tumor; Glioma; Photodynamic diagnosis; Protein kinase inhibitor

Indexed keywords

2 (1 HEXYLOXETHYL) 2 DEVINYLPYROPHEOPHORBIDE A; 2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; 4 (3 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMINOLEVULINIC ACID; BOHEMINE; BREAST CANCER RESISTANCE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; GEFITINIB; GENISTEIN; HEMATOPORPHYRIN; HEME; HOE 33342; IMATINIB; IRINOTECAN; METHOTREXATE; MITOXANTRONE; OLOMOUCINE; PHEOPHORBIDE; PHEOPHORBIDE A; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; PURVALANOL A; QUERCETIN; ROSCOVITINE; TOPOTECAN; UNCLASSIFIED DRUG; VERTEPORFIN;

BIOSYNTHESIS; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; DIAGNOSTIC TEST; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; FLUORESCENCE GUIDED MICROSURGERY; GLIOMA; HUMAN; MICROSURGERY; NONHUMAN; PHOTODYNAMIC DIAGNOSIS; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PORPHYRIN METABOLISM; PROTEIN FUNCTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 80053016584     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3030615     Document Type: Review

References (68)

1. Lipson, R.L.; Baldes, E.J. The photodynamic properties of a particular hematoporphyrin derivative. Arch. Dermatol. 1960, 82, 508-516.
2. Lipson, R.L.; Baldes, E.J.; Olsen, A.M. Hematoporphyrin derivative: a new aid for endoscopic detection of malignant disease. J. Thorac. Cardiovasc. Surg. 1961, 42, 623-629.
3. Lipson, R.L.; Baldes, E.J.; Olsen, A.M. Further evaluation of the use of hematoporphyrin derivative as a new aid for the endoscopic detection of malignant disease. Dis. Chest 1964, 46, 676-679.
4. Lipson, R.L.; Baldes, E.J.; Gray, M.J. Hematoporphyrin derivative for detection and management of cancer. Cancer 1967, 20, 2255-2257.
5. Gray, M.J.; Lipson, R.; Maeck, J.V.; Romeyn, D. Use of hematoporphyrin derivative in detection and management of cervical cancer. Am. J. Obstet. Gynecol. 1967, 99, 766-771.
6. Sanderson, D.R.; Fontana, R.S.; Lipson, R.L.; Baldes, E.J. Hematoporphyrin as a diagnostic tool. A preliminary report of new techniques. Cancer 1972, 30, 1368-1372.
7. Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380-387.
8. Dougherty, T.J.; Kaufman, J.E.; Goldfarb, A.; Weishaupt, K.R.; Boyle, D.; Mittelman, A. Photoradiation therapy for the treatment of milignant tumors. Cancer Res. 1978, 39, 2628-2635.
9. Stummer, W.; Novotny, A.; Stepp, H.; Goetz, C.; Reulen, H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 2000, 93, 1003-1013.
10. Floeth, F.W.; Stummer, W. The value of metabolic imaging in diagnosis and resection of cerebral gliomas. Nat. Clin. Pract. Neurol. 2005, 1, 62-63.
11. Shinoda, J.; Yano, H.; Yoshida, S.; Okumura, A.; Kaku, Y.; Iwata, T. Sakai, N. Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J. Neurosurg. 2003, 99, 597-603.
12. Kajimoto, Y.; Kuroiwa, T.; Miyatake, S.; Ichioka, T.; Miyashita, M.; Tanaka, H.; Tsuji, M. Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J. Neurosurg. 2007, 106, 1070-1074.
13. Lacroix, M.; Abi-Said, D.; Fourney, D.R.; Gokaslan, Z.L.; Shi, W.; DeMonte, F.; Lang, F.F.; McCutcheon, I.E.; Hassenbusch, S.J.; Holland, E.; Hess, K.; Michael, C.; Miller, D.; Sawaya, R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95, 190-198.
14. Hentschel, S.J.; Sawaya, R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control. 2003, 10, 109-114.
15. Stummer, W.; Pichmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.J. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicenter phase III trial. Lancet Oncol. 2006, 7, 392-401.
16. Stummer, W.; Reulen, H.J.; Vovotny, A.; Stepp, H.; Tonn, J.C. Fluorescence-guided resections of malignant gliomas-An Overview. Acta Neurochir. Suppl. 2003, 88, 9-12.
17. Latunde-Dada, G.O.; Simpson, R.J., McKie, A.T. Recent advances in mammalian haem transport. Trends Biochem. Sci. 2006, 31, 182-188.
18. Tsiftsoglou, A.S.; Tsamadou, A.I.; Papadopoulou, L.C. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol. Ther. 2006, 111, 327-345.
19. Krishnamurthy, P.; Xie, T.; Schuetz, J.D. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol. Ther. 2007, 114, 345-358.
20. Wakabayashi, K.; Tamura, A.; Saito, H.; Onishi, Y.; Ishikawa, T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev. 2006, 38, 371-391.
21. Dubakiene, R.; Kupriene, M. Scientific problems of photosensitivity. Medicina (Kaunas) 2006, 42, 619-624.
22. Hindmarsh, J.T. The porphyrias, appropriate test selection. Clin. Chim. Acta 2003, 333, 203-207.
23. Norman, R.A. Past and future: porphyria and porphyrins. Skinmed 2005, 4, 287-292.
24. Döring, F.; Walter, J.; Will J.; Föcking, M.; Boll, M.; Amasheh, S.; Clauss, W.; Daniel, H. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J. Clin. Invest. 1998, 101, 2761-2767.
25. Novotny, A.; Xiang, J.; Stummerm W.; Teuscher, N.S.; Smith, D.E.; Keep, R.F. Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem. 2000, 75, 321-328.
26. Whitaker, C.J.; Battah, S.H.; Forsyth, M.J.; Edwards, C.; Boyle, R.W.; Matthews, E.K. Photosensitization of pancreatic tumour cells by delta-aminolaevulinic acid esters. Anticancer Drug Des. 2000, 15, 161-170.
27. Rodriguez, L.; Batlle, A.; Di Venosa, G.; MacRobert, A.J.; Battah, S.; Daniel, H.; Casas, A. Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumours. Int. J. Biochem. Cell Biol. 2006, 38, 1530-1539.
28. Kennedy, J.C.; Pottier, R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for PDT. J. Photochem. Photobiol. B: Biol. 1992, 14, 275-292.
29. Schneckenburger, H.; König, K.; Kunzi-Rapp, K.; Westphal-Frösch, C.; Rück, A. Time-resolved in-vivo fluorescence of photosensitizing porphyrins. J. Photochem. Photobiol. B: Biol. 1993, 21, 143-147.
30. Weishaupt, K.R.; Gomer, C.J.; Dougherty, T.J. Idntification of singlet oxygen as the cytotoxic agent in photoinactivation of murine tumors. Cancer Res. 1976, 36, 2326-2329.
31. Pottier, R.; Truscott, T.G. The photochemistry of hematoporphyrin and related systems. Int. J. Radiat. Biol. 1986, 50, 421-452.
32. Loh, C.S.; Vernon, D.; McRobert, A.J.; Bedwell, J.; Bown, S.G.; Brown, S.B. Endogenous porphyrin distribution induced by 5-aminolevulinic acid in the tissue layer of the gastrointestinal tract. J. Photochem. Photobiol. B: Biol. 1993, 20, 47-54.
33. Takahashi, K.; Ikeda, N.; Nonoguchi, N.; Kajimoto, Y.; Miyatake, S.; Hagiya, Y.; Ogura, S.; Nakagawa, H.; Ishikawa, T.; Kuroiwa, T. Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-induced fluorescence. Neuro-Oncology 2011, In Press. (doi: 10.1093/neuonc/nor116).
34. Hagiya, Y.; Adachi, T.; Ogura, S.; An, R.; Tamura, A.; Nakagawa, H.; Okura, I.; Mochizuki, T.; Ishikawa, T. Nrf2-dependent induction of human ABC transporter ABCG2 and hemeoxygenase-1 in HepG2 cells by photoactivation of porphyrins: Biochemical implications for cancer cell response to PDT. J. Exp. Ther. Oncol. 2008, 7, 153-167.
35. Gupta, N.; Martin, P.M.; Miyauchi, S.; Ananth, S.; Herdman, A.V.; Martindale, R.G.; Podolsky, R.; Ganapathy, V. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem. Biophys. Res. Commun. 2006, 343, 571-577.
36. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670.
37. Allikmets, R.; Schriml, L.M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998, 58, 5337-5339.
38. Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.; Cristensen, B.; Brangi, M.; Greenberger, L.; Dean, M.; Fojo, T.; Bates, S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transporter genes. Cancer Res. 1999, 59, 8-13.
39. Wakabayashi, K.; Nakagawa, H.; Adachi, T.; Kii, I.; Kobatake, E.; Kudo, A.; Ishikawa, T. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J. Exp. Ther. Oncol. 2006, 5, 205-222.
40. Wakabayashi, K.; Nakagawa, H.; Tamura, A.; Koshiba, S.; Hoshijima, K.; Komada, M.; Ishikawa, T. Intramolecular disulfide bond is a critical checkpoint determining degradative fates of ABC transporter ABCG2 protein. J. Biol. Chem. 2007, 282, 27841-27846.
41. Wakabayashi-Nakao, K.; Tamura, A.; Furukawa, T.; Nakagawa, H.; Ishikawa, T. Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. Adv. Drug Deliv. Rev. 2009, 61, 66-72.
42. Nakagawa, H.; Wakabayashi-Nakao, K.; Tamura, A.; Toyoda, Y.; Koshiba, S.; Ishikawa, T. Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of human ATP-binding cassette transporter ABCG2. FEBS J. 2009, 276, 7237-7252.
43. Ishikawa, T.; Nakagawa, H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J. Exp. Ther. Oncol. 2009, 8, 5-24.
44. Allen, J.D.; Schinkel, A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. 2001, 1, 427-434.
45. Stewart, C.F.; Leggas, M.; Scheutz, J.D.; Panetta, J.C.; Cheshire, P.J.; Peterson, J. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004, 64, 7491-7499.
46. Jonker, J.W.; Buitelaar, M.; Wagenaar, F.; van der Valk, M.A.; Scheffer, G.L.; Scheper, R.J.; Plosch, T.; Kuipers, F.; Oude Elferink, R.P.J.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA 2002, 99, 15649-15654
47. Saito, H.; Hirano, H.; Nakagawa, H.; Fukami, T.; Oosumi, K.; Murakami, K.; Kimura, H.; Kouchi, T.; Konomi, M.; Tao, E., et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther. 2006, 317, 1114-1124.
48. Tamura, A.; Watanabe, M.; Saito, H.; Nakagawa, H.; Kamachi, T.; Okura, I.; Ishikawa, T. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol. Pharmacol. 2006, 70, 287-296.
49. Tamura, A.; Onishi, Y.; An, R.; Koshiba, S.; Wakabayashi, K.; Hoshijima, K.; Priebe, W.; Yoshida, T.; Kometani, S.; Matsubara, T.; Mikuriya, K.; Ishikawa, T. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab. Pharmacokinet. 2007, 22, 428-440.
50. An, R.; Hagiya, Y.; Tamura, A.; Li, S.; Saito, H.; Tokushima, D.; Ishikawa, T. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm. Res. 2009, 26, 449-458.
51. Ishikawa, T.; Nakagawa, H.; Hagiya, Y.; Nonoguchi, N.; Miyatake, S.; Kuroiwa, T. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Adv. Pharmacol. Sci. 2010, 2010, 587306.
52. Robey, R.W.; Steadman, K.; Polgar, O.; Bates, S.E. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol. Ther. 2005, 4, 187-194.
53. Busch, T.M.; Hahn, S.M. Multidrug resistance in photodynamic therapy. Cancer Biol. Ther. 2005, 4, 195-196.
54. Liu, W.; Baer, M.R.; Bowman, M.J.; Pera, P.; Zheng, X.; Morgan, J.; Pandey, R.A.; Oseroff, A.R. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of PDT by inhibiting ABCG2. Clin. Cancer Res. 2007, 13, 2463-2470.
55. Ishikawa, T.; Sakurai, A.; Kanamori, Y.; Nagakura, M.; Hirano, H.; Takarada, Y.; Yamada, K.; Fukushima, K.; Kitajima, M. High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol. 2005, 400, 485-510.
56. Saito, H.; An, R.; Hirano, H.; Ishikawa, T. Emerging new technology: QSAR analysis and MO calculation to characterize the interaction of protein kinase inhibitors with human ABC transporter ABCG2 (BCRP). Drug Metab. Pharmacokinet. 2010, 25, 72-83.
57. Desuzinges-Mandon, E.; Arnaud, O.; Martinez, L.; Huché, F.; Di Pietro, A.; Falson, P. ABCG2 transports and transfers heme to albumin through its large extracellular loop. J. Biol. Chem. 2010, 285, 33123-33133.
58. Noble, M.E.; Endicott, J.A.; Johnson, L.N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303, 1800-1805
59. Danceyand, J.; Sausville, E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2003, 2, 296-313.
60. Nurse, P.M. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci. Rep. 2002, 22, 487-499.
61. Porter, P.L.; Malone, K.E.; Heagerty, P.J.; Alexander, G.M.; Gatti, L.A.; Firpo, E.J.; Daling, J.R.; Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 1997, 3, 222-225.
62. Tsihlias, J.; Kapusta, L.; Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 1990, 50, 401-423.
63. Ahmed-Belkacem, A.; Pozza, A.; Muñoz-Martínez, F.; Bates, S.E.; Castanys, S.; Gamarro, F.; Di Pietro, A.; Pérez-Victoria, J.M. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res. 2005, 65, 4852-4860.
64. Zhang, S.; Yang, X.; Coburn, R.A.; Morris, M.E. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol. 2005, 70, 627-639.
65. Lagas, J.S.; van Waterschoot, R.A.; van Tilburg, V.A.; Hillebrand, M.J.; Lankheet, N.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 2009, 15, 2344-2351.
66. Kannan, P.; Telu, S.; Shukla, S.; Ambudkar, S.V.; Pike, V.W.; Halldin, C.; Gottesman, M.M.; Innis, R., Hall, M. The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem. Neurosci. 2011, 2, 82-89.
67. Tamura, A.; An, R.; Hagiya, Y.; Hoshijima, K.; Yoshida, T.; Mikuriya, K.; Ishikawa, T. Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems. Expert Opin. Drug Metab. Toxicol. 2008, 4, 255-272.
68. Matsuo, H.; Takada, T.; Ichida, K.; Nakamura, T.; Nakayama, A.; Ikebuchi, Y.; Ito, K.; Kusanagi, Y.; Chiba, T.; Tadokoro, S., et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout. A function-based genetic analysis in a Japanese population. Sci. Trans. Med. 2009, 1, 5ra11.